NASDAQ:AXDX Accelerate Diagnostics (AXDX) Stock Price, News & Analysis $0.04 +0.04 (+∞) As of 05/14/2025 This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Accelerate Diagnostics Stock (NASDAQ:AXDX) 30 days 90 days 365 days Advanced Chart Get Accelerate Diagnostics alerts:Sign Up Key Stats Today's Range N/A50-Day Range$0.03▼$1.1852-Week Range N/AVolume53.64 million shsAverage Volume479,639 shsMarket Capitalization$857,000.00P/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingStrong Buy Company OverviewAccelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms. It also provides the Accelerate PhenoTest, a test kit for the system, which provides identify and antibiotic susceptibility testing results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. Accelerate Diagnostics, Inc. was incorporated in 1982 and is headquartered in Tucson, Arizona.Read More… Accelerate Diagnostics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks35th Percentile Overall ScoreAXDX MarketRank™: Accelerate Diagnostics scored higher than 35% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Accelerate Diagnostics.Read more about Accelerate Diagnostics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Accelerate Diagnostics are expected to grow in the coming year, from ($2.30) to ($2.00) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Accelerate Diagnostics is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Accelerate Diagnostics is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.94% of the float of Accelerate Diagnostics has been sold short.Short Interest Ratio / Days to CoverAccelerate Diagnostics has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Accelerate Diagnostics has recently increased by 1.57%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAccelerate Diagnostics does not currently pay a dividend.Dividend GrowthAccelerate Diagnostics does not have a long track record of dividend growth. Sustainability and ESG4.7 / 5Environmental Score-1.62 Percentage of Shares Shorted1.94% of the float of Accelerate Diagnostics has been sold short.Short Interest Ratio / Days to CoverAccelerate Diagnostics has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Accelerate Diagnostics has recently increased by 1.57%, indicating that investor sentiment is decreasing. News and Social Media1.5 / 5News Sentiment-0.36 News SentimentAccelerate Diagnostics has a news sentiment score of -0.36. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.69 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Accelerate Diagnostics this week, compared to 1 article on an average week.MarketBeat Follows2 people have added Accelerate Diagnostics to their MarketBeat watchlist in the last 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Accelerate Diagnostics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $22,885.00 in company stock.Percentage Held by Insiders43.60% of the stock of Accelerate Diagnostics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 17.14% of the stock of Accelerate Diagnostics is held by institutions.Read more about Accelerate Diagnostics' insider trading history. Receive AXDX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Accelerate Diagnostics and its competitors with MarketBeat's FREE daily newsletter. Email Address AXDX Stock News HeadlinesAccelerate Diagnostics (NASDAQ:AXDX) Coverage Initiated at StockNews.comMay 22 at 1:39 AM | americanbankingnews.comAccelerate Diagnostics Delays 10-Q Filing Amid BankruptcyMay 16, 2025 | tipranks.comThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, it surged 239%. And in 2024, it soared another 171% on the year… But what if I told you there was a way to target those types of “peak Nvidia” profit opportunities in 24 hours or less?May 22, 2025 | Timothy Sykes (Ad)Accelerate Diagnostics (AXDX) Projected to Post Earnings on WednesdayMay 12, 2025 | americanbankingnews.comAccelerate Diagnostics Initiates Chapter 11 Restructuring ProceedingMay 10, 2025 | nasdaq.comAccelerate Diagnostics files for Chapter 11 bankruptcy, seeks asset sale amid financial strainMay 9, 2025 | bizjournals.comAccelerate Diagnostics, Inc.: Accelerate Diagnostics Files for Chapter 11 Protection and Agrees to Terms to Sell Substantially All AssetsMay 9, 2025 | finanznachrichten.deAccelerate Diagnostics Files for Chapter 11 BankruptcyMay 8, 2025 | tipranks.comSee More Headlines AXDX Stock Analysis - Frequently Asked Questions How were Accelerate Diagnostics' earnings last quarter? Accelerate Diagnostics, Inc. (NASDAQ:AXDX) issued its quarterly earnings data on Thursday, March, 20th. The medical research company reported ($0.37) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.50) by $0.13. The medical research company had revenue of $2.82 million for the quarter, compared to analysts' expectations of $3 million. When did Accelerate Diagnostics' stock split? Accelerate Diagnostics shares reverse split on Wednesday, July 12th 2023. The 1-10 reverse split was announced on Wednesday, July 12th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, July 12th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. Who are Accelerate Diagnostics' major shareholders? Accelerate Diagnostics' top institutional shareholders include Griffin Asset Management Inc. (3.38%) and Simplex Trading LLC. Insiders that own company stock include Jack Phillips, Larry Michael Mertz, David Patience and Steven Reichling. View institutional ownership trends. How do I buy shares of Accelerate Diagnostics? Shares of AXDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Accelerate Diagnostics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Accelerate Diagnostics investors own include Himax Technologies (HIMX), Sangamo Therapeutics (SGMO), Magnachip Semiconductor (MX), Universal Display (OLED), Energy Transfer (ET), Fluidigm (FLDM) and Netflix (NFLX). Company Calendar Last Earnings3/20/2025Today5/22/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Analytical instruments Sub-IndustryMeasuring And Control Equipment Current SymbolNASDAQ:AXDX CIK727207 Webacceleratediagnostics.com Phone(520) 365-3100Fax520-269-6580Employees220Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($2.34) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-61,620,000.00 Net Margins-471.83% Pretax Margin-444.14% Return on EquityN/A Return on Assets-191.66% Debt Debt-to-Equity RatioN/A Current Ratio1.50 Quick Ratio1.34 Sales & Book Value Annual Sales$11.70 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value($1.37) per share Price / BookN/AMiscellaneous Outstanding Shares25,210,000Free Float14,125,000Market Cap$857,000.00 OptionableOptionable Beta0.22 Social Links A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free Report This page (NASDAQ:AXDX) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredMan who predicted $100K Bitcoin sees a huge run coming for another coin …Sure enough, Bitcoin took off on the exact day Juan said it would. It's up more than 40% since the election...Weiss Ratings | SponsoredTrump Predicts Dollar DownfallREAD THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... ...Augusta Precious Metals | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon’s backup plan for AIElon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Accelerate Diagnostics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Accelerate Diagnostics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.